Compare EVTL & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTL | CUE |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.6M | 233.5M |
| IPO Year | 2021 | 2017 |
| Metric | EVTL | CUE |
|---|---|---|
| Price | $0.74 | $31.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $12.70 | ★ $120.00 |
| AVG Volume (30 Days) | ★ 5.1M | 345.6K |
| Earning Date | 03-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $0.52 | $0.17 |
| 52 Week High | $7.35 | $45.50 |
| Indicator | EVTL | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 52.87 |
| Support Level | $0.52 | $23.47 |
| Resistance Level | $1.42 | $33.11 |
| Average True Range (ATR) | 0.06 | 4.89 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 78.50 | 45.37 |
Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a world-wide aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero-emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.